MannKind Corp. said Monday it had netting $59.7 million from a secondary offering of almost 8.4 million shares of common stock.

The Valencia biotech announced the offering last week but did not publically price it. Chief Executive Alfred Mann, who is the company’s principal stockholder, bought 1 million shares.

The company had 103.6 million shares as of June 30.

MannKind’s first product, an inhaled fast-acting diabetes drug called Afresa, is being reviewed by the U.S. Food and Drug Administration.

MannKind shares were unchanged at $7.54 in Monday trading on the Nasdaq.